Comparison of the effect of combining botulinum toxin and cross-linked hyaluronic acid with non cross-linked hyaluronic acid in the treatment of icepick acne scar

Evaluation of the efficacy and safety of botulinum toxin type A injection with cross-linked hyaluronic acid in comparison with non cross-linked hyaluronic acid in the treatment of patients with icepick acne scar: A double blind controlled randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210718051930N1

Enrollment

Registered

2021-07-30

Start date

2021-09-06

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

icepick acne scar patients. Acne vulgaris

Interventions

Intervention 1: Intervention group 1: For patients in this group, a combination of botulinum toxin type A and cross-linked hyaluronic acid is injected once. For injection, botulinum toxin type A: Dysp

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: All patients with icepick acne scar in the range of 18 to 40 years Having informed consent to participate in the study Possibility to attend visit and follow-up sections

Exclusion criteria

Exclusion criteria: Active acne Inflammation or herpes simplex virus infection at the site of the procedure Taking anticoagulants or NSAIDs within 48 hours before and in patients with platelet dysfunction or thrombocytopenia Serious internal disease Accompanying disease at the treatment site

Design outcomes

Primary

Measure	Time frame
Qualitative intensity of scar. Timepoint: At the beginning of the study, 1 month later and then 3 and 6 months later. Method of measurement: Photography with Visioface.;Quantitative intensity of scar. Timepoint: At the beginning of the study, 1 month later and then 3 and 6 months later. Method of measurement: Determine the depth of the scar by photography with Visioface.;The rate of improvement in scar. Timepoint: 1 month after starting treatment and then 3 and 6 months later. Method of measurement: according to Global Aesthetic Improvement Scale (GAIS).	—

Measure

Time frame

Qualitative intensity of scar. Timepoint: At the beginning of the study, 1 month later and then 3 and 6 months later. Method of measurement: Photography with Visioface.;Quantitative intensity of scar. Timepoint: At the beginning of the study, 1 month later and then 3 and 6 months later. Method of measurement: Determine the depth of the scar by photography with Visioface.;The rate of improvement in scar. Timepoint: 1 month after starting treatment and then 3 and 6 months later. Method of measurement: according to Global Aesthetic Improvement Scale (GAIS).

—

Secondary

Measure	Time frame
Side effects. Timepoint: 1 month after starting treatment and then 3 and 6 months later. Method of measurement: Clinical evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Behrangi

Iran University of Medical Sciences

elham.behrangi@gmail.com+98 21 6651 7341

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026